A Phase II Study of Tri-weekly XELIRI with Bevacizumab for patient with unresectable or recurrent Colorectal Cancer as first -line chemotherapy. - A Phase II Study of Tri-weekly XELIRI with Bevacizumab for patient with unresectable or recurrent Colorectal Cancer as first -line chemotherapy.(KSCC1101)

Kyushu Study group of Clinical Cancer0 个研究点目标入组 35 人开始时间: 2011年7月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.co-mobility, such as infection, heart failure, history of cardiac infarction, liver cirrhosis, viral hepatitis type b , jaundice, kidney failure, uncontrolled hypertension, diabetes, interstitial lung disease, lung fibrosis, pulmonary emphysema. 2.coelomic fluid which need therapy( pleural effusion, abdominal dropsy, pericardial fluid) 3.history of the severe hypersensitivity 4.active other malignancies. 5.history of mental disorder, central nerve disorder, cerebral vascular disorder. 6. prior radiotherapy for primary and metastases tumors 7.brain metastasis 8.evidence of bleeding diathesis, intestinal paralysis , ileus, peptic ulcer, traumatic bone fracture 9.watery stools or grade 2 or more diarrhea 10. requiring anti-thrombogenic therapy to prevent thrombosis 11.requiring immunosuppressant and steroid drug 12. receiving atazanavir sulfate 13.pregnant or lactating woman 14. treatment history of irinotecan 15.not appropriate for the study at the physician's assessment

发起方

Kyushu Study group of Clinical Cancer